Table 2—

Metabolic parameters in the fasting state

PlaceboMetforminRosiglitazone
Before treatment
 Glucose (mmol/l)7.14 ± 0.258.23 ± 0.527.39 ± 0.37
 Insulin (pmol/l)67 ± 1163 ± 1253 ± 15
 FFA (mmol/l)0.66 ± 0.070.51 ± 0.060.64 ± 0.05
 HbAlc (%)6.11 ± 0.226.95 ± 0.276.80 ± 0.33
 TG (mmol/l)2.19 ± 0.951.31 ± 0.141.50 ± 0.29
 Cholesterol (mmol/l)4.77 ± 0.374.56 ± 0.254.68 ± 0.15
 LDL (mmol/l)2.71 ± 0.342.79 ± 0.252.86 ± 0.12
 HDL (mmol/l)1.10 ± 0.061.17 ± 0.091.13 ± 0.08
After treatment
 FPG (mmol/l)7.23 ± 0.316.72 ± 0.38*6.76 ± 0.34
 Insulin (pmol/l)61 ± 743 ± 5*40 ± 4*
 FFA (mmol/l)0.56 ± 0.060.54 ± 0.060.58 ± 0.08
 HbAlc (%)6.12 ± 0.196.27 ± 0.22§6.44 ± 0.34
 TG (mmol/l)1.52 ± 0.411.22 ± 0.381.39 ± 0.33
 Cholesterol (mmol/l)4.71 ± 0.324.44 ± 0.195.01 ± 0.23
 LDL (mmol/l)2.99 ± 0.332.59 ± 0.163.21 ± 0.14
 HDL (mmol/l)1.18 ± 0.071.28 ± 0.091.23 ± 0.08
  • Data are means ± SEM. FPG, fasting plasma glucose, TG, triglyceride.

  • *

    * P < 0.01 vs. placebo,

  • P < 0.05 vs. baseline study (Student paired t test in individual groups),

  • P < 0.09 vs. placebo,

  • §

    § P < 0.03 vs. placebo.